Staphefekt SA.100(Staphefekt SA.100) - 药物靶点：Peptidoglycan_在研适应症：金黄色葡萄球菌感染_专利_临床

概要

基本信息

药物类型

酶

别名-

靶点

Peptidoglycan

作用方式

抑制剂

作用机制

肽聚糖抑制剂

治疗领域

感染

在研适应症

金黄色葡萄球菌感染

非在研适应症-

原研机构

Swiss Federal Institute of TechnologyMicreos Pharmaceuticals AG

Micreos Human Health BV

在研机构

Swiss Federal Institute of TechnologyMicreos Pharmaceuticals AG

Micreos Human Health BV

非在研机构-

权益机构-

最高研发阶段临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与 Staphefekt SA.100 相关的临床结果

登录后查看更多信息

100 项与 Staphefekt SA.100 相关的转化医学

登录后查看更多信息

100 项与 Staphefekt SA.100 相关的专利（医药）

登录后查看更多信息

2

项与 Staphefekt SA.100 相关的文献（医药）

2022-05-17·Antimicrobial Agents and Chemotherapy2区 · 医学

Linker-Improved Chimeric Endolysin Selectively Kills Staphylococcus aureus In Vitro , on Reconstituted Human Epidermis, and in a Murine Model of Skin Infection

2区 · 医学

Article

作者: Badoux, Paul ; Offerhaus, Mark ; Leyva-Castillo, Juan M. ; Selvakumar, Lavanja ; Loessner, Martin J. ; van der Zwart, Mathijs ; Eichenseher, Fritz ; Frieling, Johan ; Geha, Raif S. ; McKellar, James ; Janssen, Ferd ; Schmelcher, Mathias ; de Rooij, Bob ; Herpers, Bjorn L. ; Röhrig, Christian

Staphylococcus aureus causes a broad spectrum of diseases in humans and animals. It is frequently associated with inflammatory skin disorders such as atopic dermatitis, where it aggravates symptoms.

Case Reports in Dermatology

Successful Treatment of Chronic Staphylococcus aureus-Related Dermatoses with the Topical Endolysin Staphefekt SA.100: A Report of 3 Cases

作者: Pasmans, Suzanne G M A ; Totté, Joan E E ; van Doorn, Martijn B

Staphylococcus aureus plays an important role in skin and soft tissue infections and contributes to the pathophysiology of complex skin disorders such as atopic dermatitis. Bacterial resistance against commonly used antibiotics has increased considerably in the last decades demanding alternative treatment approaches. We present 3 cases where patients with chronic and recurrent S. aureus-related dermatoses were successfully treated with Staphefekt SA.100. Staphefekt SA.100 is a recombinant phage endolysin for topical skin application that specifically targets both methicillin-sensitive and methicillin-resistant S. aureus. As a consequence of its specific mechanism of action, bacterial resistance is unlikely to develop. In our 3 cases, resistance induction was not observed. Our results indicate that targeted treatment with Staphefekt might be an attractive alternative for (long-term) classical antibiotic therapy, and confirmatory randomized controlled trials are warranted to evaluate its clinical efficacy and safety.

100 项与 Staphefekt SA.100 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
金黄色葡萄球菌感染	临床前	瑞士	Swiss Federal Institute of Technology	2022-04-13
金黄色葡萄球菌感染	临床前	荷兰	Micreos Human Health BV	2022-04-13
金黄色葡萄球菌感染	临床前	瑞士	Micreos Pharmaceuticals AG	2022-04-13